Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenic Disorders, Schizoaffective Disorder
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot.
- Trial name
- NCT00088465
- Testing
- Intramuscular olanzapine depot
- Where
- 92 sites in United States, Argentina and 23 more
- Volunteers
- 931 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
iTBS Can Increase Frontal Dopamine Release in PET Dopamine Imaging.
Aim: 1. To confirm that patients with predominant negative symptoms in schizophrenia have deficits in frontal cortical dopamine release when compared with healthy control and patients with positive symptoms. 2.
- Trial name
- NCT05448430
- Testing
- Theta burst stimulation
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Central South University
Schizophrenia, Schizoaffective Disorder
Galantamine for Cognition in People With Schizophrenia
This study is a double-blind, placebo-controlled trial of the nicotinic receptor agonist, galantamine, for the improvement of memory and attention in people with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00320736
- Testing
- galantamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
The primary objective of this study is to evaluate the efficacy of TV-44749 in adult participants with schizophrenia. A key secondary objective is to further evaluate the efficacy of TV-44749 based on additional parameters in…
- Trial name
- SOLARIS (NCT05693935)
- Testing
- TV-44749
- Where
- 82 sites in United States, Bulgaria and 3 more
- Volunteers
- 675 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Depression
Ecologically Valid Virtual Tasks vs Paper-pencil Methods in Cognitive Rehabilitation in Patients With Schizophrenia and Depression
Schizophrenia is heterogeneous and often disabling a disease that affects 1% of the population. Current psychopharmacological treatment significantly eliminates the presence of positive symptoms (especially delusions and…
- Conditions
- Schizophrenia, Depression, Cognitive Impairment
- Trial name
- NCT04598906
- Testing
- Virtual environment rehabilitation, Paper-pencil rehabilitation
- Where
- Czechia
- Volunteers
- 35 people
- Sponsor
- National Institute of Mental Health, Czech Republic
Schizophrenia
A Long-Term Study of JNS007ER in Patients With Schizophrenia
The purpose of this study is to assess the safety of JNS007ER 3-12 mg once daily in patients with schizophrenia over a long term period.
- Trial name
- NCT01561898
- Testing
- Paliperidone extended-release (JNS007ER)
- Volunteers
- 228 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia
This pilot study is an eight-week, randomized, double-blind, placebo-controlled, escalating dose trial of the novel vigilance-promoting drug, modafinil, added to a stable dose of clozapine in 40 patients with schizophrenia or…
- Trial name
- NCT00573417
- Testing
- modafinil
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia
A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia
The primary objective of this study is to evaluate the efficacy of seroquel in the treatment of patients with acute schizophrenia compared with risperidone by evaluating the change of PANSS total score from the baseline to week 6.
- Trial name
- NCT00817648
- Testing
- Quetiapine, risperidone
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Prevalence of Cardiovascular Disorders in Patients Aged 40 and More With Schizophrenia
Schizophrenia is a psychiatric disorder, affecting 600,000 patients in France. Patients with schizophrenia have life expectancy decrease from 10 to 20 years because of cardiovascular death.
- Trial name
- SCHIZO-CV (NCT05174533)
- Testing
- Data collection
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Université de Reims Champagne-Ardenne
Schizophrenia
Improving Quality of Informal Care for People With Schizophrenia
The goal of this clinical trial is to learn if a new support program can improve the quality of informal care for people with schizophrenia in rural China. Informal care means the unpaid care given by family members.
- Trial name
- NCT07781748
- Testing
- Dyadic Multicomponent Intervention (DMI), Dyadic Benefit-Finding Intervention (DBFI)
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Chinese University of Hong Kong
Psychosis of Childhood Borderline, Psychotic Disorder
Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability
The main objective of this study is to establish whether there are differences in self-recognition and self/other distinction in subjects with psychological vulnerability compared to healthy volunteer controls.
- Trial name
- ALTER-EGO (NCT04945278)
- Testing
- Double mirror device ALTER-EGO, EASE test
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Schizophrenia
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.
A multicenter, randomized, double-blind, placebo-controlled, dose-increasing phase Ib/II clinical trial to evaluate the safety, tolerance and pharmacokinetic characteristics of JX11502MA capsules administered multiple times in…
- Trial name
- NCT06356389
- Testing
- JX11502MA
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Jingxin Pharmaceutical Co., Ltd.
Patients With Schizophrenia, Relatives
Influence of Environmental Factors and Schizophrenia
Schizophrenia is a chronic and severe mental disorder with a lifetime prevalence of about 1 per cent, the symptoms can be very disabling and causing a heavy medical and socioeconomic.
- Trial name
- Envschi (NCT03296384)
- Testing
- Clinical and environmental evaluation
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia
Aripiprazole Once-monthly in Patients With Schizophrenia
To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A…
- Trial name
- NCT01959035
- Testing
- Aripiprazole once-monthly
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders
RUFUS - Group Rumination-focused CBT for Negative Symptoms
Abstract - -- Introduction: Psychosis spectrum disorders are characterized by both positive and negative symptoms, but whereas there is good effect of treatment on positive symptoms, there is still a scarcity of effective…
- Trial name
- RUFUS (NCT05851950)
- Testing
- group rumination focused cognitive behavioural therapy, Treatment as usual
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia, Schizoaffective Disorder
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
- Trial name
- NCT02411526
- Testing
- ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Zogenix, Inc.
Obese, Cigarette-smoking
Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia
The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.
- Conditions
- Obese, Cigarette-smoking, Schizophrenia
- Trial name
- NCT02736474
- Testing
- Naltrexone, Bupropion
- Volunteers
- 22 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Bipolar Disorder
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
The purpose of this study is to investigate the efficacy and safety of long-term psychopharmacotherapy in schizophrenia or bipolar disorder in terms of psychopathology and side effects.
- Trial name
- NCT00330226
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.